Tango Therapeutics, Inc. Increase (Decrease) in Accounts Payable, Trade
Tango Therapeutics, Inc. (TNGX) reported Increase (Decrease) in Accounts Payable, Trade of $1.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-11
- Tango Therapeutics, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was -$759.00K.
- Tango Therapeutics, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was $1.78M, a 9.51% increase year-over-year.
- Tango Therapeutics, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was -$1.23M.
- Tango Therapeutics, Inc. increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was -$344.00K, a 111.29% decline year-over-year.
- Tango Therapeutics, Inc. increase (decrease) in accounts payable, trade for fiscal 2025 was -$825.00K.
- Tango Therapeutics, Inc. increase (decrease) in accounts payable, trade for fiscal 2024 was -$1.18M.
- Tango Therapeutics, Inc. increase (decrease) in accounts payable, trade for fiscal 2023 was -$1.71M, a 255.42% decline from fiscal 2022.
- Tango Therapeutics, Inc. increase (decrease) in accounts payable, trade for fiscal 2022 was $1.10M, a 10.96% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$759.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.03M 10-Q · filed 2026-08-11 | -$205.00K derived: sum of 3 quarters · filed 2026-08-11 | -$549.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.78M 10-Q · filed 2026-05-13 | $554.00K derived: sum of 2 quarters · filed 2026-05-13 | $210.00K derived: sum of 3 quarters · filed 2026-05-13 | -$670.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.57M derived: sum of 2 quarters · filed 2026-03-05 | -$2.46M derived: sum of 3 quarters · filed 2026-08-11 | -$825.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | -$344.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$1.22M derived: sum of 2 quarters · filed 2026-08-11 | $406.00K 10-Q · filed 2025-11-04 | -$2.10M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$880.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $750.00K 10-Q · filed 2026-08-11 | -$1.76M derived: sum of 3 quarters · filed 2026-08-11 | $1.29M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.63M 10-Q · filed 2026-05-13 | -$877.00K derived: sum of 2 quarters · filed 2026-05-13 | $2.17M derived: sum of 3 quarters · filed 2026-05-13 | -$596.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $540.00K derived: sum of 2 quarters · filed 2026-03-05 | -$2.23M derived: sum of 3 quarters · filed 2026-03-05 | -$1.18M 10-K · filed 2026-03-05 |
| 2024-09-30 | $3.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $281.00K derived: sum of 2 quarters · filed 2025-11-04 | $1.32M 10-Q · filed 2025-11-04 | $1.24M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | -$2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$1.72M 10-Q · filed 2025-08-05 | -$1.81M derived: sum of 3 quarters · filed 2026-03-05 | -$3.77M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $1.04M 10-Q · filed 2025-05-12 | $954.00K derived: sum of 2 quarters · filed 2026-03-05 | -$1.00M derived: sum of 3 quarters · filed 2026-03-05 | -$2.21M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | -$88.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$2.04M derived: sum of 2 quarters · filed 2026-03-05 | -$3.26M derived: sum of 3 quarters · filed 2026-03-05 | -$1.71M 10-K · filed 2026-03-05 |
| 2023-09-30 | -$1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$3.17M derived: sum of 2 quarters · filed 2024-11-06 | -$1.62M 10-Q · filed 2024-11-06 | -$2.66M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $340.00K 10-Q · filed 2024-08-07 | -$700.00K derived: sum of 3 quarters · filed 2025-02-27 | $3.79M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.55M 10-Q · filed 2024-05-08 | $512.00K derived: sum of 2 quarters · filed 2025-02-27 | $5.00M derived: sum of 3 quarters · filed 2025-02-27 | $3.01M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.45M derived: sum of 2 quarters · filed 2025-02-27 | $1.46M derived: sum of 3 quarters · filed 2025-02-27 | $1.10M 10-K · filed 2025-02-27 |
| 2022-09-30 | $4.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $2.50M derived: sum of 2 quarters · filed 2023-11-08 | $2.14M 10-Q · filed 2023-11-08 | $2.50M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$2.36M 10-Q · filed 2023-08-07 | -$1.99M derived: sum of 3 quarters · filed 2023-08-07 | -$3.87M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$359.00K 10-Q · filed 2023-05-09 | $6.00K derived: sum of 2 quarters · filed 2023-05-09 | -$1.88M derived: sum of 3 quarters · filed 2023-05-09 | -$1.68M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$1.52M derived: sum of 2 quarters · filed 2023-03-27 | -$1.32M derived: sum of 3 quarters · filed 2023-03-27 | $1.23M 10-K · filed 2023-03-27 |
| 2021-09-30 | -$1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$1.69M derived: sum of 2 quarters · filed 2022-11-10 | $867.00K 10-Q · filed 2022-11-10 | $1.12M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $192.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $2.75M 10-Q · filed 2022-08-10 | $3.01M derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $2.56M 10-Q · filed 2022-05-11 | $2.81M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $257.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $1.17M 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $914.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |